| Literature DB >> 33718662 |
H Carson Eisenbeisz1, Adam R Bleeker1, Daniel C Terveen1,2, John P Berdahl1,2.
Abstract
PURPOSE: The objective of this series is to report the early post-operative visual outcomes of a novel triple procedure utilizing Descemet membrane endothelial keratoplasty (DMEK) plus light adjustable lens (LAL) in two patients (four eyes).Entities:
Keywords: Astigmatism; Descemet membrane endothelial keratoplasty (DMEK); Fuchs' dystrophy; Light adjustable lens (LAL); Triple cataract surgery
Year: 2021 PMID: 33718662 PMCID: PMC7933706 DOI: 10.1016/j.ajoc.2021.101061
Source DB: PubMed Journal: Am J Ophthalmol Case Rep ISSN: 2451-9936
Preoperative vision, glare testing, and endothelial cell counts for all eyes.
| Patient A OD | Patient A OS | |
|---|---|---|
| UCVA | 20/20 -2 | 20/20 -1 |
| BCVA | 20/20 | 20/20 |
| BAT | 20/50 | 20/50 |
| Endothelial cell density (cells/mm3) | 2358 | 2232 |
| Central corneal thickness (μm) | 584 | 589 |
| UCVA | 20/40 | 20/60 |
| BCVA | 20/15 -2 | 20/15 -1 |
| BAT | 20/50 | 20/150 |
| Endothelial cell density (cells/mm3) | 2262 | 2653 |
| Central corneal thickness (μm) | 571 | 566 |
Manifest refractions and uncorrected visual acuity (UCVA) at various points pre- and postoperatively. Treatment refers to adjustment of light adjustable lens (LAL) using a digital light delivery device (DLDD). The DLDD is similar to a slit lamp. Patients are dilated prior to each light treatment. The surgeon uses the DLDD to focus UV light on the LAL either condensing or dispersing light sensitive polymers based on the patient's residual refractive error. A total of three light treatments can be completed before final lock-in. Lock-in treatments use a higher intensity of ultraviolet light to solidify the remaining untreated polymer.
| Patient A OD | Patient A OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Sphere | Cylinder | Axis | UCVA | Sphere | Cylinder | Axis | UCVA | |
| Preop | 3.00 | −0.75 | 120 | 3.00 | −0.25 | 55 | ||
| 1 week postop* | 0.25 | 0 | NA | 20/50 -2 | 0.5 | 0 | NA | 20/20 -2 |
| 2 weeks postop | 0.5 | −0.75 | 100 | 20/20 -1 | 0.5 | −0.5 | 66 | 20/20 + 2 |
| 1° treatment | 1.25 | −1.25 | 127 | 20/20 | 0.75 | −0.75 | 50 | 20/20 |
| 2° treatment | −0.25 | −0.5 | 87 | 20/15 | −0.5 | −0.5 | 140 | 20/15 |
| 1° Lock-in | 0.25 | 0 | NA | 20/15 | 0.25 | −0.5 | 130 | 20/15 |
| 2° Lock-in | NA | NA | NA | NA | 0.25 | 0 | NA | 20/20 |
| Sphere | Cylinder | Axis | UCVA | Sphere | Cylinder | Axis | UCVA | |
| Preop | 1.00 | −2.00 | 74 | 20/40 | 1.00 | −1.00 | 100 | 20/60 |
| 1 week postop* | 0 | 0 | NA | 20/15 | −1.00 | −0.5 | 135 | 20/30 -1 |
| 2 weeks postop | −0.5 | 0 | NA | 20/20 -3 | ||||
| 1° treatment | 1.00 | −1.25 | 65 | 20/20 -1 | 0 | −0.5 | 120 | Jaeger 3 |
| 2° treatment | −1.25 | −0.5 | 165 | 20/20 -2 | −1.00 | −0.25 | 121 | Jaeger 1+ |
| 3° treatment | NA | NA | NA | NA | −1.25 | −0.5 | 113 | Jaeger 1 |
| 1° Lock-in | 0 | −0.25 | 106 | 20/15 -2 | −1.75 | 0 | NA | Jaeger 1+ |
* indicates time of rebubbling for partial graft detachment.